H.C. Wainwright raised the firm’s price target on Ardelyx (ARDX) to $18 from $10 and keeps a Buy rating on the shares. The firm is “encouraged” by the company having announced the successful new patent with expiration in November 2042.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx: Strong Ibsrela Momentum, De-Risked CIC Upside, and Patent-Backed Undervaluation Support Buy Rating
- Ardelyx reports Q4 EPS 0c, consensus 1c
- Ardelyx Posts Strong 2025 Results, Projects 2026 Growth
- Ardelyx options imply 14.7% move in share price post-earnings
- ARDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?